早産(子宮収縮抑制)治療薬市場:パイプラインレビュー(2019年下半期)

【英語タイトル】Premature Labor (Tocolysis) - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA20MY0074)・商品コード:GDATA20MY0074
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月25日
・ページ数:46
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Premature Labor (Tocolysis) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor – Pipeline Review, H2 2019, provides an overview of the Premature Labor (Women’s Health) pipeline landscape.

Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Premature Labor – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Premature Labor (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Labor (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Premature Labor (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Women’s Health).
- The pipeline guide reviews pipeline therapeutics for Premature Labor (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Premature Labor (Women’s Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Premature Labor (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Women’s Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Premature Labor (Women’s Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Premature Labor (Women’s Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Labor (Tocolysis) – Overview
Premature Labor (Tocolysis) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Premature Labor (Tocolysis) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Labor (Tocolysis) – Companies Involved in Therapeutics Development
Dare Bioscience Inc
GlaxoSmithKline Plc
ObsEva SA
Premature Labor (Tocolysis) – Drug Profiles
OBE-022 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
progesterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
retosiban – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Acute Inflammation and Premature Labor – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Premature Labor – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Labor (Tocolysis) – Dormant Projects
Premature Labor (Tocolysis) – Discontinued Products
Premature Labor (Tocolysis) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Premature Labor (Tocolysis), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Premature Labor (Tocolysis) - Pipeline by Dare Bioscience Inc, H2 2019
Table 11: Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 12: Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2019
Table 13: Premature Labor (Tocolysis) - Dormant Projects, H2 2019
Table 14: Premature Labor (Tocolysis) - Discontinued Products, H2 2019

【掲載企業】

Dare Bioscience Inc
GlaxoSmithKline Plc
ObsEva SA

★調査レポート[早産(子宮収縮抑制)治療薬市場:パイプラインレビュー(2019年下半期)] (コード:GDATA20MY0074)販売に関する免責事項を必ずご確認ください。
★調査レポート[早産(子宮収縮抑制)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆